Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2023-09-22 Regulatory Filings
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
bioMérieux dépose une double demande d'agrément 510(k) et de dérogation CLIA auprès de la FDA pour le panel BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST)
Regulatory Filings Classification · 100% confidence The document is a press release from bioMérieux dated September 22, 2023, announcing that they have filed for 510(k) clearance and CLIA waiver from the FDA for a new diagnostic panel (BIOFIRE® SPOTFIRE® R/ST). This is an announcement regarding regulatory action and product development, not a formal periodic financial report (like 10-K or IR) or a transcript. Since it is a specific announcement about regulatory submission/approval status for a product, it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory update that isn't covered by other codes like ER, AR, or LTR. It is not a report itself, but an announcement of an action taken.
2023-09-22 French
Août 2023 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as mandated by French commercial code and AMF regulations. This type of filing, which reports on share structure and voting rights, is most closely aligned with the general category of regulatory announcements or specific filings related to share capital changes. Given the options, it is a specific regulatory disclosure about share structure, but none perfectly match the French 'Droits de Vote' filing type. However, it is a formal regulatory filing detailing share structure and voting rights, which is often categorized under general regulatory filings or sometimes related to capital changes. Since it is a mandatory monthly disclosure of voting rights and total shares, it fits best under the general 'Regulatory Filings' (RNS) as a specific, recurring regulatory report that doesn't fit the other specific categories like 10-K, ER, or DIV. It is not a management change (MANG), director dealing (DIRS), or dividend notice (DIV). It is a formal regulatory filing.
2023-09-05 French
Rapport Financier Semestriel 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2023' (Semi-Annual Financial Report 2023) for bioMérieux SA. It contains comprehensive financial statements, including the consolidated income statement, balance sheet, cash flow statement, and notes to the financial statements for the six-month period ending June 30, 2023. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2023
2023-09-04 French
Rapport Financier Semestriel 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2023' (Semi-Annual Financial Report 2023) for bioMérieux SA. It contains comprehensive consolidated financial statements, including the income statement, balance sheet, and notes for the six-month period ending June 30, 2023. As it is a full interim report containing substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2023
2023-09-04 French
bioMérieux – First-Half 2023 Results
Earnings Release Classification · 100% confidence The document explicitly states it contains the "bioMérieux – First-Half 2023 Results" and provides detailed consolidated financial statements, including sales figures, income statements, and analysis for the six months ended June 30, 2023. This structure, covering a period shorter than a full year with comprehensive financial detail, aligns perfectly with the definition of an Interim / Quarterly Report. The document is substantial (over 50,000 characters) and contains the full results, not just an announcement of results, ruling out RPA or ER. H1 2023
2023-09-01 English
bioMérieux?–?Résultats semestriels au 30 juin 2023
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – Résultats semestriels au 30 juin 2023" (bioMérieux – Half-year results as of June 30, 2023). It contains detailed consolidated financial statements, key performance indicators (revenue, operating income, net income) for the first half of the year (S1 2023 vs S1 2022), and segment/geographic breakdowns. The text explicitly mentions the Board of Directors approved the audited consolidated accounts as of June 30, 2023. This content structure—a comprehensive financial review for a period shorter than a year (six months)—is characteristic of an Interim/Quarterly Report. The code 'IR' (Interim / Quarterly Report) is the most appropriate classification. H1 2023
2023-09-01 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.